Comparison of two inhalers in cases of COPD

Comparison of Inhalational Drugs Formoterol + Glycopyrronium (LABA-LAMA) vs. Formoterol + Budesonide (LABA-ICS) and outcomes in cases of COPD- Randomised Control Trial - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054973

Enrollment

Registered

2023-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J96-J99- Other diseases of the respiratory system Health Condition 2: J988- Other specified respiratory disorders

Interventions

Intervention1: NIL: NIL Control Intervention1: PATIENTS ON LABA-ICS: PATIENTS ON LABA-ICS

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to give informed consent. Patients aged above 40 years Patients of either sex.

Exclusion criteria

Exclusion criteria: Patient unwilling to give informed consent. Pregnant and lactating women. Patient is not willing to Inhalational treatment. Patient is not willing for Spirometry.

Design outcomes

Primary

Measure	Time frame
1.To determine changes in Spirometry in (LABA+LAMA) Formoterol + Glycopyrronium vs. (LABA+ICS) Formoterol + Budesonide patients. 2.To determine changes in 6-minute walk test in (LABA+LAMA) Formoterol + Glycopyrronium vs. (LABA+ICS) Formoterol + Budesonide patients. Timepoint: ONE DAY	—

Secondary

Measure	Time frame
1. To note the side effects 2. To assess the quality of lifeTimepoint: After 90 days	—

Countries

India

Contacts

Public ContactDR MADHAV MAHAWAR

SHRI BM PATIL MEDICAL COLLEGE , HOSPITAL AND RESEARCH INSTITUTE

keertivardhandk@gmail.com9986896644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026